Safest NSAIDs in Coronary Artery Disease
If you must use an NSAID in a patient with coronary artery disease, naproxen (≤1000 mg/day) is the safest choice, but only after exhausting non-NSAID alternatives first.
Stepped-Care Approach (Follow This Algorithm)
The ACC/AHA guidelines provide a clear hierarchy for pain management in CAD patients 1:
Step 1: Non-NSAID Options (Try These First - Class I)
- Acetaminophen
- Non-acetylated salicylates
- Tramadol
- Small doses of narcotics
Step 2: If Step 1 Fails - Nonselective NSAIDs (Class IIa)
- Naproxen is reasonable if initial therapy is insufficient 1
- Use the lowest effective dose for the shortest possible time
- Add aspirin 81 mg daily with a PPI to reduce GI bleeding risk 1
Step 3: If Step 2 Fails - COX-2 Selective NSAIDs (Class IIb)
- May be considered only for intolerable discomfort despite stepped-care attempts 1
- Again, lowest dose, shortest duration
Step 4: Never Use (Class III - Harm)
- Do NOT use COX-2 selective NSAIDs when non-selective NSAIDs provide acceptable relief 1
- Avoid ibuprofen - it blocks aspirin's antiplatelet effects 2
The Evidence on Cardiovascular Risk
Mortality Data from the Danish Registry Study
A landmark study of 58,432 post-MI patients showed hazard ratios for death 1, 2, 1:
- Naproxen: 1.29 (lowest risk among NSAIDs)
- Ibuprofen: 1.50
- Diclofenac: 2.40
- Celecoxib: 2.57
- Rofecoxib: 2.80 (highest risk)
Key Principle: Risk Proportional to COX-2 Selectivity
The more COX-2 selective an NSAID, the higher the cardiovascular risk 1, 3. This occurs because COX-2 inhibition:
- Reduces endothelial prostacyclin production (protective)
- Leaves platelet thromboxane A2 production relatively unopposed (prothrombotic)
- Results in a prothrombotic imbalance
Recent Research Confirms Naproxen's Relative Safety
A 2009 study of patients recently hospitalized for serious coronary heart disease found naproxen users had the lowest adjusted rates of serious coronary events (HR 0.88,95% CI 0.66-1.17) compared to non-users, with no increased risk even at doses ≥1000 mg 4. In contrast, short-term use (<90 days) increased risk for ibuprofen (HR 1.67), diclofenac (HR 1.86), and celecoxib (HR 1.37) 4.
Critical Monitoring Requirements
When NSAIDs are used in CAD patients, monitor regularly for 1:
- Sustained hypertension or worsening blood pressure control
- Edema
- Worsening renal function
- GI bleeding
If these occur, reduce dose, discontinue the drug, or switch to alternative therapies.
Common Pitfalls to Avoid
Don't assume revascularization eliminates NSAID risk - the cardiovascular risk persists and may be amplified in established CAD 1
Don't use ibuprofen with aspirin - ibuprofen competitively inhibits aspirin's irreversible platelet inhibition, negating cardioprotection 2, 5
Don't use diclofenac - it has one of the worst cardiovascular safety profiles, comparable to COX-2 inhibitors 1, 6
Don't forget the PPI - when combining aspirin with NSAIDs, always add a proton pump inhibitor to reduce upper GI bleeding risk 1
Don't use long-term - cardiovascular risk increases within weeks of use and rises with duration 7, 8
Bottom Line for Clinical Practice
Naproxen ≤1000 mg/day is the least harmful NSAID option when pain management requires moving beyond acetaminophen, tramadol, and non-acetylated salicylates in CAD patients 1, 4, 8, 5. However, even naproxen carries some risk - the safest approach is to avoid NSAIDs entirely in this population whenever possible, using the stepped-care algorithm above.